Last reviewed · How we verify
Zoledronic acid i.v. 2 years
Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate.
Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate. Used for Treatment of hypercalcemia of malignancy, Treatment of bone metastases in patients with advanced malignancies, Treatment of osteoporosis in postmenopausal women.
At a glance
| Generic name | Zoledronic acid i.v. 2 years |
|---|---|
| Sponsor | Ludwig-Maximilians - University of Munich |
| Drug class | Bisphosphonate |
| Target | Hydroxyapatite |
| Modality | Small molecule |
| Therapeutic area | Oncology, Bone Diseases |
| Phase | Phase 3 |
Mechanism of action
Bisphosphonates like zoledronic acid bind to hydroxyapatite in bone, inhibiting osteoclast-mediated bone resorption. This leads to a decrease in bone turnover and an increase in bone mineral density.
Approved indications
- Treatment of hypercalcemia of malignancy
- Treatment of bone metastases in patients with advanced malignancies
- Treatment of osteoporosis in postmenopausal women
Common side effects
- Renal impairment
- Hypocalcemia
- Nausea
- Vomiting
- Fever
- Fatigue
- Bone pain
- Musculoskeletal pain
Key clinical trials
- Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis (PHASE3)
- Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older (PHASE3)
- Study of AK156 in Primary Osteoporosis Patients (PHASE3)
- Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (PHASE3)
- Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis (PHASE4)
- Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions (PHASE3)
- THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) (PHASE2)
- Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zoledronic acid i.v. 2 years CI brief — competitive landscape report
- Zoledronic acid i.v. 2 years updates RSS · CI watch RSS
- Ludwig-Maximilians - University of Munich portfolio CI